High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders. — CFSMEATLAS
High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders.
Klein, R, Berg, P A · European journal of medical research · 1995
Quick Summary
Researchers found that patients with ME/CFS and fibromyalgia syndrome (FMS) often have similar antibodies in their blood—proteins the immune system produces that may attack the body's own tissues. About 62% of ME/CFS patients and 73% of FMS patients had antibodies against serotonin, a chemical important for mood and pain regulation. Interestingly, these antibodies were also found in family members of affected patients, suggesting a genetic component may play a role.
Why It Matters
This study provides immunological evidence that ME/CFS and FMS may share a common autoimmune mechanism involving antibodies against serotonin and neural antigens. If validated in larger studies, this could support recognition of these disorders as related autoimmune conditions and potentially guide targeted therapeutic approaches. The finding of familial antibody clustering also has implications for genetic screening and disease prevention in at-risk relatives.
Observed Findings
62% of ME/CFS patients had antibodies to serotonin (5-HT), compared to 73% of FMS patients
43% of ME/CFS patients had antibodies to gangliosides, compared to 71% of FMS patients
38% of ME/CFS patients had antibodies to phospholipids, compared to 54% of FMS patients
55% of ME/CFS patients had at least two of the three antibody types
Antibodies to these antigens were detected in family members of both CFS and FMS patients
Inferred Conclusions
ME/CFS and FMS may represent manifestations of the same underlying autoimmune condition or clinical entity
Genetic predisposition may contribute to disease susceptibility in both ME/CFS and FMS, evidenced by familial clustering of antibodies
Serotonin-specific antibodies show stronger disease association than ganglioside or phospholipid antibodies
Both conditions may be classified as 'psycho-neuro-endocrinological autoimmune diseases' with shared immunological mechanisms
Remaining Questions
Are these antibodies present before symptom onset, and do they predict disease development in at-risk family members?
What This Study Does Not Prove
This study does not prove that these antibodies cause ME/CFS or FMS symptoms, only that they are associated with these conditions. The cross-sectional design cannot establish causality or temporal relationships. Additionally, the presence of these antibodies in family members does not definitively prove genetic inheritance versus shared environmental exposure, and it remains unclear whether antibody positivity predicts disease development or severity.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →